Rocket Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Rocket Pharmaceuticals's estimated annual revenue is currently $4M per year.
- Rocket Pharmaceuticals received $50.0M in venture funding in November 2018.
- Rocket Pharmaceuticals's estimated revenue per employee is $16,653
- Rocket Pharmaceuticals's total funding is $552.8M.
- Rocket Pharmaceuticals has 242 Employees.
- Rocket Pharmaceuticals grew their employee count by 7% last year.
Rocket Pharmaceuticals Competitors & AlternativesAdd Company
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is Rocket Pharmaceuticals?
Rocket Pharmaceuticals, Ltd is a biotechnology company focused on seeking cures through molecular and gene therapy. We are developing first-in-class treatments for patients with rare and often devastating orphan diseases using a lentiviral-based gene therapy approach. We have developed rewarding partnerships with a number of leading international research institutions as well as with centers of manufacturing and cell processing expertise, while building an internal team to drive the research, development, clinical and regulatory programs. Ultimately we aim to launch and globally commercialize innovative gene therapies in disease areas with high unmet need. For more information, please visit www.rocketpharma.com.keywords:N/A
Number of Employees
Employee Growth %
Rocket Pharmaceuticals News
Zero analysts have issued estimates for Rocket Pharmaceuticals' earnings, with the highest EPS estimate coming in at ($0.63) and the lowest...
Rocket Pharmaceuticals (NASDAQ:RCKT Get Rating)'s stock had its buy rating reaffirmed by Needham & Company LLC in a report issued on...
Rocket Pharmaceuticals to Present at Upcoming Investor Conferences. March 29, 2022 07:00 AM Eastern Daylight Time. CRANBURY, N.J.--(BUSINESS WIRE)--Rocket...
CRANBURY, N.J.--(BUSINESS WIRE)--Mar 22, 2021-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces updated preliminary clinical data from its Phase 1 trial of R ...
CRANBURY, N.J.--(BUSINESS WIRE)--Mar 9, 2021-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces that the U.S. Food and Drug Administration (FDA) has granted R ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|
Rocket Pharmaceuticals Funding
|2018-11-27||$50.0M||Undisclosed||BofA Merrill Lynch||Article|